Hostname: page-component-cd9895bd7-fscjk Total loading time: 0 Render date: 2024-12-23T14:20:39.620Z Has data issue: false hasContentIssue false
  • English
  • Français

MONITORING REGISTRIES AT ITALIAN MEDICINES AGENCY: FOSTERING ACCESS, GUARANTEEING SUSTAINABILITY

Published online by Cambridge University Press:  08 December 2015

Simona Montilla ,
Entela Xoxi ,
Pierluigi Russo ,
Americo Cicchetti  and
Luca Pani
Simona Montilla
Affiliation:
Italian Medicines Agency (AIFA) [email protected]
Entela Xoxi
Affiliation:
Italian Medicines Agency (AIFA)
Pierluigi Russo
Affiliation:
Italian Medicines Agency (AIFA)
Americo Cicchetti
Affiliation:
Università Cattolica del Sacro Cuore
Luca Pani
Affiliation:
Italian Medicines Agency (AIFA)
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives: The AIFA (Agenzia Italiana del Farmaco—Italian Medicines Agency) Monitoring Registries track the eligibility of patients and the complete flow of treatments, guaranteeing appropriateness in use of pharmaceutical products, according to approved indications.

Methods: This study describes the Italian pharmaceutical context and the aims and functioning of AIFA Monitoring Registries, focusing on the applications to the Managed Entry Agreements (MEAs) and HTA approaches.

Results: The AIFA Monitoring Registries System has been operational in Italy since 2005. In 2012, the system became part of the NHS Information Technology system, aiming at enhancing appropriate use of pharmaceuticals and efficiency of the administrative activity. Currently, seventy-six medicines are monitored through the system, corresponding to fifty-eight therapeutic indications; individual treatments recorded are more than 515,000, for a population of approximately 505,000 patients. For each monitored product, patients eligible for treatment are registered in the specific therapeutic indication dynamic monitoring database to collect epidemiologic and clinical data, including data on the safety profile, and ex-post information missing at first evaluation stage.

Conclusions: AIFA Monitoring Registries allow the evaluation of the pharmaceuticals’ performance in clinical practice and may promote innovation and quicker access to medicines at affordable prices, for the benefit of patients.

Keywords

Drug monitoringRegistriesReal clinical practice data collectionManaged entry agreements
Type
Theme Submissions
Information
International Journal of Technology Assessment in Health Care , Volume 31 , Issue 4 , 2015 , pp. 210 - 213
Copyright
Copyright © Cambridge University Press 2015 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1. Folino-Gallo, P, Montilla, S, Bruzzone, M, Martini, N. Pricing and reimbursement of pharmaceuticals in Italy. Eur J Health Econ. 2008;9:305–310. doi: 10.1007/s10198-008-0114-5.Google Scholar
2. Martini, N, Folino-Gallo, P, Montilla, S. Pharmaceutical pricing and reimbursement information: Italy. Vienna: Gesundheit Osterreich GmbH/Geschaftsbereich OBIG (GOG/OBIG); 2007.Google Scholar
3. Osservatorio Nazionale sull’Impiego dei Medicinali, Agenzia Italiana del Farmaco. L’uso dei Farmaci in Italia. Roma: Rapporto nazionale; 2013.Google Scholar
4. Ferrario, A, Kanavos, P. Managed entry agreements for pharmaceuticals: The European experience. EmiNet, The London School of Economics and Political Science, 2013. (pp. 1–150). http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/mea_report_en.pdf (accessed March 20, 2015).Google Scholar
5. Garrison, LP, Towse, A, Briggs, A, et al. Performance-based risk-sharing arrangements—Good practices for design, implementation, and evaluation: Report of the ISPOR Good Practices for Performance-Based Risk-Sharing Arrangements Task Force. Value Health. 2013;16:703–719. doi:10.1016/j.jval.2013.04.011.Google Scholar
6. Siviero, PD. Managed-entry agreements as a way of enabling patient access to innovation. Eur J Oncol Pharm. 2012;3–4:30–31.Google Scholar
7. Russo, P, Mennini, FS, Siviero, PD, Rasi, G. Time to market and patient access to new oncology products in Italy: A multistep pathway from European context to regional health care providers. Ann Oncol. 2010;21:2081–2087. doi:10.1093/annonc/mdq097.Google Scholar
8. Espín, J, Rovira, J, García, L. Experiences and impact of European risk-sharing schemes focusing on oncology medicines. EmiNet, Andalusian School of Public Health; 2011.Google Scholar
9. Garattini, L, Casadei, G. Risk sharing agreements: What lessons from Italy? Int J Technol Assess Health Care. 2011;27169–172. doi:10.1017/S0266462311000079.Google Scholar